EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische StudieKlinische Studie (Phase II)

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Jean-Yves Douillard, Yutaka Nishiwaki, Johan Vansteenkiste, Shinzoh Kudoh, Danny Rischin, Richard Eek, Takeshi Horai und 8 weitere

Journal of Clinical Oncology · 20.02.2023 · 41 (6) · 1162-1171

DOI: 10.1200/jco.22.02499 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.02.2023. Verfasst von Masahiro Fukuoka und 19 weiteren Autor:innen. Beteiligte Einrichtung: From the Kinki University School of Medicine, Osaka City University School of Medicine, and AstraZeneca, Osaka, Tokushima University School of Medici…. Die Arbeit wurde bisher 12-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS This was a randomized, double-blind, parallel-group, multicenter phase II trial. Two hundred ten patients with advanced NSCLC who were previously treated with one or two chemotherapy regimens (at least one containing platinum) were randomized to receive either 250-mg or 500-mg oral doses of gefitinib once daily. RESULTS Efficacy was similar for the 250- and 500-mg/d groups. Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively. Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response. Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Drug-related toxicities were more frequent in the higher-dose group. Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively. CONCLUSION Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients. At 250 mg/d, gefitinib had a favorable AE profile. Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.

Autor:innen und Institutionen

  • From the Kinki University School of Medicine, Osaka City University School of Medicine, and AstraZeneca, Osaka, Tokushima University School of Medicine, Tokushima, National Cancer Center, Central Hospital, and Japanese…

Zitieren

APA

Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J. Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., Eek, R., Horai, T., Noda, K., Takata, I., Smit, E., Averbuch, S., Macleod, A., Feyereislova, A., Dong, R. P., & Baselga, J. (2023). Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 41(6), 1162-1171. https://doi.org/10.1200/jco.22.02499

Vancouver

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 2023;41(6):1162-1171. doi:10.1200/jco.22.02499

BibTeX
@article{Fukuoka2023,
  author = {Fukuoka, Masahiro and Yano, Seiji and Giaccone, Giuseppe and Tamura, Tomohide and Nakagawa, Kazuhiko and Douillard, Jean-Yves and Nishiwaki, Yutaka and Vansteenkiste, Johan and Kudoh, Shinzoh and Rischin, Danny and Eek, Richard and Horai, Takeshi and Noda, Kazumasa and Takata, Ichiro and Smit, Egbert and Averbuch, Steven and Macleod, Angela and Feyereislova, Andrea and Dong, Rui-Ping and Baselga, José},
  title = {Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {6},
  pages = {1162--1171},
  doi = {10.1200/jco.22.02499}
}
Kostenlos starten →